Patents Assigned to Rosetta Genomics Ltd
  • Patent number: 7618814
    Abstract: The present invention relates to a first group of novel genes, here identified as genomic address messenger or GAM genes, and a second group of novel operon-like genes, here identified as genomic record or GR genes. GAM genes selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 8607 GAM genes, and 1096 GR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM and GR genes and specific functions and utilities thereof, for detecting expression of GAM and GR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Grant
    Filed: November 16, 2003
    Date of Patent: November 17, 2009
    Assignee: Rosetta Genomics Ltd.
    Inventor: Itzhak Bentwich
  • Patent number: 7592441
    Abstract: Described herein are novel polynucleotides associated with liver cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of liver cancer. Also described herein are methods that can be used to identify modulators of the disease-associated polynucleotides. Also described herein are methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and Microarray analysis.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: September 22, 2009
    Assignee: Rosetta Genomics Ltd
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 7250496
    Abstract: The present invention relates to a first group of novel genes, here identified as “genomic address messenger” or “GAM” genes, and a second group of novel operon-like genes, here identified as “genomic record” or “GR” genes. GAM genes selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 20600 GAM genes, and 6635 GR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM and GR genes and specific functions and utilities thereof, for detecting expression of GAM and GR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: July 31, 2007
    Assignee: Rosetta Genomics Ltd.
    Inventor: Isaac Bentwich
  • Patent number: 7217807
    Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: May 15, 2007
    Assignee: Rosetta Genomics Ltd
    Inventor: Itzhak Bentwich